Melanoma Institute Australia
Welcome,         Profile    Billing    Logout  
 13 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Long, Georgina
NADINA, NCT04949113 / 2021-001492-16: Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

Active, not recruiting
3
423
Europe, US, RoW
Neoadjuvant ipilimumab + nivolumab, Yervoy + Opdivo, Adjuvant nivolumab, Opdivo
The Netherlands Cancer Institute, Bristol-Myers Squibb
Malignant Melanoma Stage III
01/24
12/28
ACTRN12613000737730: An open label, single centre, phase II pilot study of neoadjuvant dabrafenib + trametinib in patients with resectable AJCC Stage IIIB-C BRAF V600 mutation positive melanoma

Active, not recruiting
2
35
 
Melanoma Institute Australia, GlaxoSmithKline Australia
Melanoma
 
 
ACTRN12614001315606: A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases (ABC - Anti-PD1 Brain Collaboration Study)

Active, not recruiting
2
75
 
Melanoma Institute Australia , Melanoma Institute Australia
Melanoma Brain Metastases, Melanoma
 
 
Neo Combi, NCT01972347: Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
2
35
RoW
Dabrafenib, GSK2118436, Trametinib, GSK1120212
Melanoma Institute Australia
Melanoma
05/17
05/24
ABC, NCT02374242 / ACTRN12614001315606: Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

Active, not recruiting
2
76
RoW
Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016
Melanoma Institute Australia, Melanoma and Skin Cancer Trials Limited, Bristol-Myers Squibb
Melanoma, Brain Metastases
09/17
12/28
NeoTrio, NCT02858921: Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Active, not recruiting
2
60
RoW
Dabrafenib, Tafinlar, Trametinib, Mekinist, Pembrolizumab, Keytruda
Melanoma Institute Australia, Merck Sharp & Dohme LLC, Novartis
Melanoma
01/22
11/24
Neo PeLe, NCT04207086: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

Active, not recruiting
2
21
RoW
Pembrolizumab, Keytruda, Lenvatinib, Lenvima
Melanoma Institute Australia, Merck Sharp & Dohme LLC
Melanoma Stage III
01/23
01/33
Neo-MCC, NCT06151236: Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Recruiting
2
20
RoW
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination, Opdualag
Melanoma Institute Australia, Bristol-Myers Squibb
Merkel Cell Carcinoma
04/26
04/34
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
NCT03340129: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Recruiting
2
218
Europe, RoW
Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy
Melanoma Institute Australia, Bristol-Myers Squibb
Melanoma Stage Iv
08/24
08/25
Neo ReNi II, NCT05418972: A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma

Recruiting
2
20
RoW
Relatlimab and nivolumab fixed dose combination (FDC), Opdualag
Melanoma Institute Australia, Bristol-Myers Squibb
Stage II Melanoma
12/24
12/34
KEYNOTE-D36, NCT05309421: A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Recruiting
2
90
RoW
EVX-01, Pembrolizumab 25 MG/ML, Keytruda
Evaxion Biotech A/S, Merck Sharp & Dohme LLC
Melanoma Stage III, Melanoma Stage IV
06/25
07/25
KEYNOTE-E40, NCT05280314: Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Recruiting
2
60
Europe, US, RoW
IO102-IO103, Pembrolizumab KEYTRUDA®
IO Biotech, Theradex, Almac, Merck Sharp & Dohme LLC
Melanoma, Squamous Cell Carcinoma of Head and Neck
04/25
01/27
I-MAT, NCT04291885: Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

Recruiting
2
132
RoW
Avelumab, anti-PD-L1, Bavencio, Placebo
Melanoma and Skin Cancer Trials Limited
Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Merkel Cell Carcinoma, Stage III, Neuroendocrine Tumors, Carcinoma Neuroendocrine Skin
04/27
04/28
Neo PeLeMM, NCT05545969: Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma

Withdrawn
2
44
RoW
Pembrolizumab, Keytruda, Lenvatinib, Lenvima
Melanoma Institute Australia, Merck Sharp & Dohme LLC
Mucosal Melanoma
05/26
05/36
MatchMel, NCT02645149: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

Recruiting
2
1000
RoW
Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study
Melanoma Institute Australia, Novartis
Melanoma
07/27
12/28
NCT04834973: A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Terminated
1/2
3
RoW
tigilanol tiglate, EBC-46, pembrolizumab, Keytruda
QBiotics Group Limited, Merck Sharp & Dohme LLC
Melanoma
07/22
07/22
Menzies, Alex
MatchMel, NCT02645149: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

Recruiting
2
1000
RoW
Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study
Melanoma Institute Australia, Novartis
Melanoma
07/27
12/28

Download Options